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Abstract
Background: This systematic review aimed to identify, compare and contrast outcome domains and outcome
instruments reported in studies investigating interventions that seek to restore bilateral (two-sided) and/or binaural
(both ears) hearing in adults with single-sided deafness (SSD). Findings can inform the development of evidence-
based guidance to facilitate design decisions for confirmatory trials.
Methods: Records were identified by searching MEDLINE, EMBASE, PubMed, CINAHL, ClinicalTrials.gov, ISRCTN,
CENTRAL, WHO ICTRP and the NIHR UK clinical trials gateway. The search included records published from 1946 to
March 2020. Included studies were those as follows: (a) recruiting adults aged 18 years or older diagnosed with SSD
of average threshold severity worse than 70 dB HL in the worse-hearing ear and normal (or near-normal) hearing in
the better-hearing ear, (b) evaluating interventions to restore bilateral and/or binaural hearing and (c) enrolling
those adults in a controlled trial, before-and-after study or cross-over study. Studies that fell just short of the
participant eligibility criteria were included in a separate sensitivity analysis.
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Results: Ninety-six studies were included (72 full inclusion, 24 sensitivity analysis). For fully included studies, 37
exclusively evaluated interventions to re-establish bilateral hearing and 29 exclusively evaluated interventions to
restore binaural hearing. Overall, 520 outcome domains were identified (350 primary and 170 secondary). Speech-
related outcome domains were the most common (74% of studies), followed by spatial-related domains (60% of
studies). A total of 344 unique outcome instruments were reported. Speech-related outcome domains were
measured by 73 different instruments and spatial-related domains by 43 different instruments. There was
considerable variability in duration of follow-up, ranging from acute (baseline) testing to 10 years after the
intervention. The sensitivity analysis identified no additional outcome domains.
Conclusions: This review identified large variability in the reporting of outcome domains and instruments in
studies evaluating the therapeutic benefits and harms of SSD interventions. Reports frequently omitted information
on what domains the study intended to assess, and on what instruments were used to measure which domains.
Trial registration: The systematic review protocol is registered on PROSPERO (International Prospective Register of
Systematic Reviews): Registration Number CRD42018084274. Registered on 13 March 2018, last revised on 7th of
May 2019.
Keywords: Single-sided deafness, Outcome domains, Measurement instruments, Hearing interventions, Clinical trial
design
Background
Single-sided deafness (SSD) arises when there is normal
or near-normal hearing in one ear and a severe to pro-
found sensorineural hearing impairment in the other ear
[1]. The cause can be congenital [2, 3], sudden (e.g.
Meniere’s disease [4], idiopathic [5, 6], due to auto-
immune systemic diseases [7]); or progressive (e.g. ves-
tibular schwannoma [8–10]). Regardless, SSD can lead
to functional [11–16], psychological and social conse-
quences [17–19].
The most commonly used treatments for SSD enable
access to sounds on both sides of the head (‘bilateral’
hearing) by rerouting sounds from the impaired ear to
the hearing ear [20, 21]. This effect can be achieved with
a CROS (Contralateral Routing Of Signals) aid [20, 22–
27] or a bone-anchored hearing aid (BAHA) [28–43] as
well as other bone conduction devices like the ADHEAR
[44, 45] or SoundBite™ [34, 46–49]. Alternatively, audi-
tory input to the deaf ear can be restored (‘binaural’
hearing) by delivering sounds directly to the auditory
pathway on the side of the impaired ear using auditory
prostheses like a middle ear implant (MEI) [50, 51] or a
cochlear implant [52–73].
Understanding which of these intervention approaches
are optimal for patients with SSD should be based on ro-
bust evidence from well-designed trials [74, 75]. Cer-
tainly, with respect to health-related quality of life, there
is a known inconsistency in the choice of measurement
instruments in trials assessing the benefits of SSD inter-
ventions [76]. This inconsistency hinders comparison
and meta-analysis across studies. The evidence synthesis
in systematic reviews for example can be reliably con-
ducted only if trials assess the same outcomes and meas-
ure them in the same way [77].
The challenge of synthesising evidence from trials and
the importance of utilising valid instruments that effect-
ively measure the intended audiological outcomes has
been highlighted by Hall et al. [78]. Trialists should
ideally base their choice of outcome measures on what is
important and relevant to people making decisions
about healthcare [79–81]. The question of what outcome
domains are important and relevant to individuals with
SSD when deciding whether an intervention works has yet
to be asked in a systematic way. One attempt was made in
2017, but this was based on two discussions among pro-
fessional experts in cochlear implantation at international
conferences [1] and was intended for adoption in clinical
practice. There has been no rigorous scrutiny of outcome
reporting for rerouting and restoring interventions, no
systematic patient involvement and no specific consider-
ation of what should be recommended for clinical trials.
As a consequence, investigators adopt markedly different
study designs when assessing the clinical benefit of rerout-
ing and restoring interventions for SSD.
The Core Rehabilitation Outcome Set for Single Sided
Deafness (CROSSSD) study seeks to examine and ad-
dress problems with inconsistent outcome reporting in
SSD intervention trials. To achieve this, CROSSSD is de-
veloping a Core Outcome Set (COS) through a rigorous
evidence-based process and by actively involving all rele-
vant stakeholders in decision making. A COS is an
agreed minimum set of outcomes or outcome measures
which comprises a standardised collection of outcome
domains that should be measured and reported world-
wide, as a minimum, in all controlled trials within a re-
search area [82–85]. Our published protocol [86]
describes the process and this systematic review formed
one of the first steps.
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Objectives
The primary objective of this systematic review was to
identify those outcome domains and outcome instru-
ments reported in published clinical studies evaluating
rerouting and/or restoring interventions in adults with
SSD. This information will be used to subsequently gen-
erate a ‘long list’ of candidate outcomes to be rated by
SSD stakeholders according to whether each is import-
ant and critical to determine if an intervention works in
this clinical population as part of the development of a
Core Outcome Set (COS) [86].
There were two additional (secondary) objectives. One
was to compare and contrast outcome domains and in-
struments reported for interventions that aim to re-
establish (i) bilateral hearing (i.e. CROS aid, BAHA,
ADHEAR, SoundBite™) and (ii) binaural hearing (i.e.
MEI, CI). The other was to examine what outcome do-
mains had been assessed and outcome instruments used
as a function of time point after intervention. This infor-
mation can be used to distinguish short- and long-term
treatment-related changes. An exploratory objective was
added to examine how the long list of candidate out-
comes would be affected if the audiometric inclusion cri-
teria were more lenient than our working definition




Details of the specific review questions, search strategy,
study eligibility criteria, information sources, selection
and data collection processes, quality assessment and
data synthesis methods were published on PROSPERO
international prospective register of systematic reviews
in advance of data extraction [87]. There were no modi-
fications to this PROSPERO protocol, but the Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement [88] was modified for
reporting purposes here. A populated PRISMA (2009)
checklist can found in Additional file 1.
Study inclusion and exclusion criteria
The eligibility was defined according to PICOS (Partici-
pant, Intervention(s), Comparator(s), Outcome, Setting)
criteria. All included records assessed adults (male or fe-
male) aged 18 years or older with a diagnosis of congeni-
tal or acquired SSD. For the primary objective, diagnoses
had to meet an audiometric profile independently de-
fined through consensus [1]. For the worse-hearing ear,
this required a threshold severity worse than 70 dB HL
at audiometric frequencies ranging from 1 to 4 kHz, and
for the better-hearing ear, this required a pure tone aver-
age of ≤ 30 dB HL across the same frequency range.
Eligible interventions comprised any medical devices
designed specifically to restore bilateral (two-sided) or
binaural (both ears) hearing. Any comparators in the
study design were allowed, but studies exclusively evalu-
ating other audiological interventions such as conven-
tional hearing aids, assistive listening devices,
audiological counselling, communication strategies or
providing no intervention (unaided or placebo) were ex-
cluded. There were no restrictions on outcomes or re-
search settings.
The systematic review included records reporting ran-
domised controlled trials, quasi-randomised controlled tri-
als, non-randomised controlled trials, before-and-after
studies, cross-over studies, trial registrations and pub-
lished protocols of such ongoing studies, and systematic
reviews. Relevant systematic reviews were not subjected to
the data collection process itself but were read to ensure
all eligible records had been captured. Case control stud-
ies, cohort studies, non-systematic literature reviews (e.g.
scoping reviews), practice guidelines, expert opinions, case
series, case reports, book chapters, conference papers,
manufacturers’ articles (e.g. white papers), animal studies
and studies that use predictive modelling (e.g. prognostic
factors established by acoustic test box measurements or
studies performed with cadavers) were excluded. Original
searches were performed from 1946, or the start date of
databases, whichever was earlier, up to April 2018 inclu-
sive. The searches were updated to 18th of March 2020.
There were no restrictions on language of the publication.
During the data collection process, a small number of
records were identified where information about age-
related eligibility, audiometric thresholds or type of hear-
ing loss in either the better or poorer hearing ear were
missing. The corresponding author was contacted for
more details by email, and a decision was made regarding
inclusion in light of the new information provided. In
cases where the author did not respond, an executive deci-
sion was taken to (i) include, (ii) exclude or (iii) use for
sensitivity analysis; following discussion with one of the
two senior authors (PTK or DAH). Cases in the sensitivity
analysis were those trials or studies in which (i) partici-
pants’ audiometric profiles were close to our adopted SSD
definition but differed from those criteria by up to 20 dB
in individual frequencies either in the better or worse ear;
(ii) the corresponding author was asked to clarify the
audiometric profiles of participants but did not respond;
and (iii) ongoing studies recruiting a mixture of partici-
pants (including children aged less than 18 years of age)
and where it was not clear if results would be reported
separately for the adults (aged 18 years or over).
Information sources
Records were identified by searching electronic data-
bases of research literature including (Table 1).
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Published, unpublished and ongoing studies were identified
by electronically searching the following databases from their
inception: EMBASE, MEDLINE, PubMed, CINAHL, Clini-
calTrials.gov, ISRCTN, CENTRAL, ICTRP and the NIHR
UK Clinical Trials Gateway. Electronic searchers were run
by RK and PTK in March and April 2018 and then updated
on 18th March 2020. In addition, a hand-search was con-
ducted when reviewing the 76 published articles that had
met the eligibility criteria at the abstract and full-text screen-
ing stages. Two potential articles were identified [27, 89], but
following closer scrutiny neither met eligibility.
Search strategy
The search strategy used in this systematic review was
registered on PROSPERO [87]. Search terms for the
PubMed, EMBASE and MEDLINE databases were in-
formed by the PICOS criteria and comprised a set of
terms to identify the population combined with a set of
terms to identify relevant interventions. Where possible
using the database interface, the scope of the search was
limited to humans (not animals) and adults (not paediat-
ric). An example of the search syntax for MEDLINE and
EMBASE via OvidSP can be found in Additional file 2.
The search strategy for the other databases was modelled
on this search strategy and adapted where necessary to en-
sure the strategies were highly sensitive across each of the
database interfaces. As an example, the syntax for search
of the CENTRAL trials registry of the Cochrane Collabor-
ation can be found in Additional file 3.
Data management
RK, DAH and PTK were responsible for data manage-
ment and maintained editorial rights. All identified re-
cords were saved into a Microsoft Excel Masterfile
where records were tracked through the screening and
data collection process by a unique study identification
code.
Selection process
All records identified by all database searches were
uploaded into the EndNote software (Version X7) that
was used to remove duplicates using the records’ title,
list of authors, year of publication and journal of publi-
cation. In a few isolated cases, the abstract was also used
to double-check if there was duplication, mainly for re-
cords that were published in a different language and
the translated title or name of journal were different.
The resulting number of records were subjected to eligi-
bility screening.
Eligibility screening was carried out by RK, DAH,
CFK, SS, PP and PTK, according to the published proto-
col [87]. For each record, the title and abstract screening
decision was captured using a simple set of descriptors:
include; unsure possibly include; exclude out of scope;
exclude not SSD; exclude not adults; exclude wrong
intervention; exclude wrong trial design; incomplete ref-
erence; abstract not accessible and sensitivity analysis
(Additional file 4). Two co-authors (RK and DAH or
PTK) independently performed and/or reviewed each
step (i.e. title and abstract screening, full-text screening,
data extraction, risk of bias assessment). Records that
were included to conduct the sensitivity analysis only
were extracted by RK alone. On rare occasions where
agreement could not be reached between co-authors,
disagreements were resolved by a third reviewer (DAH
or PTK). The risk of bias assessment did not affect
which findings were included in the analyses.
Table 1 Table summarising the electronic information sources used and the number of records identified
Type of electronic search Database Date range Number of
items (n)
Academic databases Excerpta Medica dataBASE (EMBASE) via OvidSP 1974 to 18th
March 2020
1463
Medical Literature Analysis and Retrieval System Online (MEDLINE) via OvidSP 1974 to 18th
March 2020
1144
PubMed National Centre for Biotechnology Information 1946 to 18th
March 2020
1223




Clinical trial registers and/or
other sources
ClinicalTrials.gov (www.clinicaltrials.gov) 18th March 2020 193
International Standard Randomised Controlled Trials Number (ISRCTN)
Registry (www.isrctn.com)
18th March 2020 48
Cochrane Central Register of Controlled Trials (CENTRAL) 18th March 2020 962
World Health Organization (WHO) International Clinical Trials Registry
Platform (ICTRP) (www.who.int/ictrp)
18th March 2020 270
NIHR UK Clinical Trials Gateway (www.ukctg.nihr.ac.uk) 18th March 2020 67
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To enhance our data quality, data collection was
guided by a data extraction protocol (Additional file 5),
which informed the headings of the data masterfile. A
calibration exercise was conducted for ten included re-
cords and reviewed for consistency across two coders,
and the data extraction protocol was revised according
to the lessons learned. No coder was permitted to be an
author on any of the included records.
Data items
Data items included PICOS fields as described by the
PROSPERO record [87]. Participant data items relating
to the inclusion criteria for each record were as follows:
(1) SSD cause / aetiology, (2) age range, (3) mean age,
(4) age standard deviation and (5) time since SSD diag-
nosis. Intervention data items recorded were as follows:
(6) type of intervention device used and (7) time of im-
plementation of intervention (how long after the onset
of SSD the intervention was implemented). Data items
describing the trial design included (8) the comparator
device (if applicable), (9) the type of trial design and (10)
the time duration for which each intervention or com-
parator device were used.
Outcome data items were as follows: (11) the outcome
domain(s) specified by the investigators, (12) instru-
ments specified by the investigators and (13) measure-
ment time frame. Information relating to these three
data items was recorded separately for all primary and
secondary outcomes. Where authors were not explicit
about the distinction between primary and secondary
outcomes, the ‘Methods’ and ‘Results’ sections of each
article were examined to identify any relevant informa-
tion related to this distinction. If the study investigators
did not explicitly distinguish multiple outcome domains
as primary or secondary, they were all classified as
primary.
Supplementary information was also extracted from
each individual record on the following: (1) countries
where the study was conducted, (2) corresponding au-
thor contact details, (3) source title (e.g. journal), (4)
date of publication, (5) primary and/or secondary objec-
tive(s), (6) sample size, (7) description of any modifica-
tions to the study, particularly any discrepancies
between the trial protocol and the subsequent report of
the findings, and (8) any conflicts of interest identified
by the authors. For (4), the date of publication recorded
the date of the print copy, not the date of first submis-
sion, acceptance or the date of ‘online first’ publication.
For (6), the estimated sample size was recorded for on-
going clinical trials where enrolment was not yet avail-
able. If any information was not reported, then ‘not
stated’ was recorded in the corresponding field.
Where trial records had been consolidated into a sin-
gle study, the data items reported in the synthesis related
to the most recent study publication. For those records
in which several pieces of information were consolidated
for a single study, any inconsistencies between the
protocol and the final reported study findings were
noted (e.g. if the intended participant sample size was
different in the published clinical trial record in com-
parison to the final study findings publication).
Outcomes and prioritisation
The primary research question was to identify those out-
come domains and outcome instruments reported in
studies investigating interventions that seek to restore
hearing in adults with SSD. There are no validated tax-
onomies specific to the hearing field and so for our clas-
sification of outcome domains, we chose to use the
Dodd et al. [90] taxonomy. Strengths of this taxonomy
are that it has been developed specifically for trial out-
comes, is comprehensive, is not disease specific, is not
limited to patient-centered outcomes and is applicable
to trials irrespective of the field being studied. It com-
prises 38 categories across five core areas; death, physio-
logical or clinical, life impact, resource use and adverse
events. Classification of the review findings with respect
to this taxonomy was conducted by RK and PTK. Finer
breakdown of outcomes with the category ‘Ear and laby-
rinth outcomes’ was informed by a 2-day outcome do-
main grouping workshop that took place in July 2019
with members of the research steering group and the
two public research partners. Details on the individual
outcome domains review, consolidation and categorisa-
tion during the workshop can be found in the CROSSSD
study protocol [86].
Risk of bias
Given that the primary objective of this systematic re-
view concerns methodology (not therapeutic effects), we
limited the assessment of risk of bias to the data collec-
tion methods for consolidated records rather than any
analysis of the intervention-related changes. The consoli-
dated record data (e.g. outcome descriptors, published
primary / secondary findings) was critically analysed for
consistency of outcome reporting by two independent
reviewers (RK and DAH). Risk of bias was assessed by
analysing the reporting of outcomes both within and
across manuscripts reporting study findings. Bias was
determined by whether outcomes were reported pro-
spectively through trial registration or published proto-
col, and whether outcomes were reported consistently
between protocol / registration and study report. If con-
sensus could not be reached on whether outcomes had
been reported consistently, then disagreements were re-
solved by discussion with a third reviewer (PTK). No
contact was made with corresponding authors to investi-
gate the rationale of altered reporting. The quality of a
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Figure 1 displays the results of the search strategy used
to identify the relevant articles as recommended by the
PRISMA statement [91]. The search strategy yielded
5754 records from which 2554 were excluded as dupli-
cates. This resulted in a total of 3200 unique records be-
ing subjected to eligibility screening. Most exclusions
during title and abstract eligibility screening were due to
the study being out of scope (e.g. examined surgical
methods, assistive hearing devices or hearing therapy
techniques), the wrong trial design (e.g. case series, scop-
ing reviews), not recruiting SSD participants or not
recruiting adults, leaving 564 records (Fig. 1). For these,
full texts were obtained and where necessary were trans-
lated to the English language. Full-text eligibility screen-
ing enabled a further 446 records to be excluded, with
most exclusions due to participants not meeting the
working definition of SSD [1] (n = 281) or using an ineli-
gible trial design (n = 111). These exclusions left 118 re-
cords for data extraction, detailed as follows.
Fig. 1 CROSSSD Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [91]
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Full-text screening confirmed that 76 records reported
trials in which the diagnosis of SSD fully met our criteria
according to the Van de Heyning et al. [1] definition.
The remaining 30 records reported participant criteria
that narrowly missed the inclusion criteria (see eligibility
criteria section above for details) but were sufficiently
close to the criteria for inclusion in the sensitivity ana-
lysis. The 12 systematic review articles [76, 92–102]
identified by the searches were reviewed to check for
any overlooked trials or studies for inclusion, and 37
additional articles were identified by this approach. Full-
text screening established that two met the inclusion cri-
teria [72, 73], and one was included in the sensitivity
analysis [25]. The rest were excluded due to wrong trial
design (n = 18), the majority were conference papers, or
they were out of scope (n = 7) [103–109], did not fit the
audiometric criteria (n = 7) [110–116], or included chil-
dren in their studies that were not reported separately
from adults (n = 2) [117, 118]. References for the in-
cluded records are given in Additional file 6 and the data
masterfile containing information on all the data items is
available for download (Additional file 7).
A number of records were consolidated for the pur-
pose of reporting because they described the same trial
or study. Two records by Härkönen et al. [53, 54] re-
ported different measures obtained from the same group
of participants. Two records reporting on a United Sates
of America (USA) multicentre study [31, 32] were also
consolidated as they reported on the same subset of par-
ticipants. Four records [46–48, 119] reported on the
same USA trial and participants, but presented different
outcomes at different time scales so they were grouped.
A French clinical trial registration (NCT02204618) by
Marx et al. [120] was consolidated with the study find-
ings record [69]. Similarly, a Swiss clinical trial regis-
tration (NCT01749592) [121] was consolidated with
the published study findings record [66], a USA
clinical trial (NCT02259192) [122] with the equiva-
lent published record [65] and another French clin-
ical trial (NCT02966366) [123] with its published
record [67]. Two records by the Arndt et al. group
reported on the same 11 participants but presented
outcomes at 6 months [59] and at 12 months [52],
so they were consolidated. Conversely, one compos-
ite article [38] reported the methods and results of
five separate trials. Data from this article were ex-
tracted as five distinct studies. This re-classification
led to a final dataset of 78 records reporting 72
studies that met full eligibility, and 31 records
reporting 24 studies for the sensitivity analysis
(Fig. 1). Of the 72 studies included, 37 assessed
rerouting interventions, 29 studies assessed restoring
interventions and just 6 studies directly evaluated
both types of interventions.
Data collection process
During eligibility screening, corresponding authors for
17 records were contacted to ask for more detail on the
participant audiometric eligibility criteria or the defin-
ition of SSD adopted (see Additional file 8). Six authors
responded with new information that allowed the
screeners to come to a decision to (i) include for data
extraction and synthesis (n = 1) [124], (ii) exclude from
data extraction (n = 2) [125, 126] or (iii) include for sen-
sitivity analysis (n = 3) [123, 127, 128]. Three emails were
undeliverable, for these we decided to exclude two re-
cords [129, 130] but include one record [131] which was
a clinical trial intending to recruit participants with SSD.
Six authors did not respond [99, 132–136], and so we
decided to include all six for sensitivity analysis. Two au-
thors responded but their responses did not adequately
clarify the query; one record [137] was included for sen-
sitivity analysis and one [138] was excluded from data
extraction.
The most common SSD diagnoses were sudden idio-
pathic or unknown cause (n = 218, 41%) and vestibular
schwannoma (n = 134, 25%). The majority of rerouting
intervention studies were conducted in the USA (n = 25,
66%). Restoring intervention studies were conducted in
the USA (n = 8, 36%), Belgium and Germany (n = 4,
19%). Studies recruited a median of 10.5 participants
(mean = 25.3, range 3–160). Most multicentre studies
(n = 7) were conducted to evaluate restoring interven-
tions rather than rerouting interventions.
Outcome domains
To address our first objective, we examined the outcome
domains extracted data from the 72 included studies
and classified them for reporting using the Dodd et al.
[90] taxonomy. Overall, 350 primary and 170 secondary
data items were categorised across 19 of the 38 tax-
onomy categories (Table 2). Just over half (55%) of the
reported outcome domains were physiological or clinical
outcomes in the ear and labyrinth category (194 primary
and 90 secondary outcome domain data items). Within
this category, the most common items were from
speech-related domains (e.g. speech in noise and speech
in quiet), spatial-related domains (e.g. localisation and
spatial hearing), hearing thresholds and tinnitus loud-
ness. Life impact was the next most frequently reported
core area (33%; 120 primary and 50 secondary outcome
domain data items). The most popular categories within
life impact were delivery of care and quality of life. We
observed that investigators sometimes reported multiple
assessments of the same outcome domain within a
study, and so the caveat to these findings is that these
frequencies do somewhat over-estimate the proportion
of included studies reporting the outcome domain. A
complete list of all reported outcome domains can be
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Table 2 Summary of primary and secondary outcome domains and data items across all 72 included studies, classified according to


































Death 1: Mortality /
survival






194 55.4% 90 52.9% 15 3
7: Eye
outcomes
0 – 1 – 1 0
9: General
outcomes




3 – 3 1.8% 2 0
21: Psychiatric
outcomes




2 – 0 – 1 0
Life impact 25: Physical
functioning
2 – 5 3.3% 2 3
26: Social
functioning
1 – 3 2.9% 1 2
27: Role
functioning




7 2.0% 5 3.3% 5 3
29: Cognitive
functioning
2 – 3 2.9% 1 2
30: Global
quality of life
55 15.7% 16 9.4% 7 0
31: Perceived
health status











0 – 1 – 0 1
Resource use 34: Economic 2 – 2 1.2% 2 0
35: Hospital 1 – 0 – 1 0
37: Societal /
carer burden





11 3.1% 5 2.9% 3 0
Cannot code 0: Cannot code 5 1.4% 17 10.0% N/A N/A
Total 350 170 55 18
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found in Additional file 9. A total of 22 outcome domain
data items (4%) could not be coded because they were not
clearly defined by the authors. Overall, 73 unique outcome
domains were reported across the 72 included studies, 55
primary and 18 secondary outcome domains (Table 2).
Outcome instruments
Our first objective also asked about the outcome instru-
ments used to measure the domains. For reporting pur-
poses, measurement instruments are summarised
according to whether they were as follows: (1) investiga-
tor administered, (2) patient-reported outcome measures
(PROMs) and (3) unclear or unknown (Table 3). Within
each of these categories, a finer breakdown was per-
formed that was relevant to the instrument category (e.g.
PROMs could be a numerical rating scale, multi-item
questionnaire or diary).
Collating information about the measurement instru-
ments reported in the 72 studies revealed a large num-
ber of ways to measure the domains of interest and the
fact that no single instrument was used by all studies.
We observed that reporting was strongly biased towards
benefits not harms. Counting the exact number of in-
struments is not straightforward because some of the in-
struments were reported both as global scores and
subscale scores across different studies and different au-
thors administered the same instrument to assess differ-
ent outcome domains. For example, the Glasgow
Hearing Aid Benefit Profile (GHABP) [139] was reported
in various forms under hearing handicap, pre-
intervention disability, device benefit, device use, satis-
faction, and residual (aided) disability. Regarding the Ab-
breviated Profile of Hearing Aid Benefit (APHAB) [140],
performance was most often reported as a subscale not a
global score, including all three speech communication
subscales (Ease of communication, Reverberation and
Background noise subscales). For the purposes of report-
ing here, the different forms reported by the authors all
contribute to the data item counts and so the numbers
may over-estimate the number of instruments per se.
For that reason, we refer to these data as measurement
‘methods’ not ‘instruments’. A summary of the number
of methods used to measure the outcomes across the
most popular Dodd’s taxonomy categories is given in
Table 3. For transparency, a comprehensive listing of all
methods can be found in Additional file 10, organised
according to the domains within Dodd’s taxonomy
categories.
Considering the ear and labyrinth outcome domains,
the 18 outcome domains were assessed by 133 different
measurement methods. A description of the more popu-
lar methods is given in Table 4. The most common ap-
proach was an investigator-administered psychophysical
instrument. This was true for all of the speech-related
domains (i.e. speech in noise, speech in quiet and speech
hearing), spatial localisation and hearing thresholds.
Speech performance was most often measured by a
speech reception threshold, although there were many
different testing methods. There was no clear preferred
method for measuring speech in quiet, while speech in
noise was most often assessed using the Hearing in
Noise Test (HINT) [141]. However, even here the choice
of background noise was not consistent across studies.
Localisation performance was most often measured by
localisation accuracy using a horizontal circular or semi-
circular array of loudspeakers. However, again the num-
ber of loudspeakers and angular separation between
sound sources varied across studies. Perhaps unsurpris-
ingly, hearing thresholds were most often assessed using
pure-tone audiometry which tends to have a more stan-
dardised testing method. Tinnitus loudness was com-
monly measured using a visual analogue scale (VAS),
which is a form of PROM.
The seven global quality of life outcome domains were
assessed by 36 different measurement methods. A de-
scription of the more popular methods is given in
Table 5. The most common method of assessment was a
PROM, in the form of a multi-item questionnaire. Most
frequently reported were the Speech, Spatial and Qual-
ities of Hearing (SSQ) [16], Glasgow Benefit Inventory
(GBI), single-sided deafness (SSD) questionnaire and
Tinnitus Handicap Inventory (THI) [142].
The 12 delivery of care (Satisfaction / patient prefer-
ence) outcome domains were assessed by 37 different
measurement methods. A description of the more popu-
lar methods is given in Table 6. Once again, the most
common method of assessment was a PROM, in the
form of a multi-item questionnaire. The most frequently
reported were the Abbreviated Profile of Hearing Aid
Benefit (APHAB) [140] and the Glasgow Hearing Aid
Benefit Profile (GHABP).
Comparing the report of outcome domains and
instruments across interventions
One of our secondary objectives was to compare and
contrast outcome domains and instruments reported for
interventions that aim to re-establish (i) bilateral hearing
(i.e. CROS aid, BAHA, ADHEAR, SoundBite™) through
rerouting and (ii) binaural hearing (i.e. MEI, CI) through
restoring.
Across the 72 included studies, 37 assessed rerouting
interventions only and 29 assessed restoring interven-
tions only. The remainder assessed both interventions in
the same study design and so are not included in this
comparison. Generally speaking, the two intervention
approaches assessed the same outcome domains. But
there were several notable exceptions. Tinnitus-related
outcomes were almost exclusively limited to studies
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evaluating restoring interventions (reported 43 times) ra-
ther than rerouting interventions (reported once). The
same was true for brain-related assessments of neural
activity (restoring studies reported three times; rerouting
studies none). In contrast, rerouting studies were also
much more concerned about aversiveness (reported 10
times) than were restoring studies (reported once). Fur-
thermore, all dental outcomes were limited to rerouting
studies. In fact, all eight reports came from a single
study evaluating the SoundBite™ intraoral device [46–48,
119]. A summary of the split across the interventions is
given in Additional file 9.
Overall, restoring intervention studies reported a
greater proportion of investigator-administered tests
than PROMs, while rerouting intervention studies
reported more of a balance of these two instrument
types. It was not possible to determine the effect of
intervention on the choice of measurement methods be-
cause the number of times each method used was gener-
ally very small. Perhaps the most striking effect observed
was that speech hearing was assessed using the APHAB
[140] ease of communication subscale in rerouting stud-
ies (reported 13 times) much more often than in restor-
ing studies (reported just once).
Use of measures over time frame
For both primary and secondary outcomes, there was
significant variability in the duration of follow-up period,
ranging from acute (baseline) testing to 10 years post-
intervention. There was notable inconsistency in the
Table 3 Summary of the number of more common measurement methods used to assess treatment outcomes in each domain
category from the Dodd et al. [90] taxonomy. Only items where there were more than 10 reports of the outcome domain
(Additional file 9) and only those methods reported more than once across the 72 included studies are selected for reporting here.
See Additional file 10 for a complete list of instruments
Outcome
domains

















Physiological or clinical core area, 6: ear and labyrinth outcomes
Hearing
thresholds
8 1 – – – – – –
Speech in noise 47 – – – – 2 – –
Speech in quiet 18 – – – – 2 – –
Speech hearing 6 – – – – 3 – –
Tinnitus
loudness
1 – – – 2 – – –
Spatial hearing 1 – – – – 3 – –
Localisation 33 – – – – 1 – –
Quality of
hearing
– – – – 2 1 – 2
Reverberation – – – – 1 1 – –




– – – – – 9 – –
Hearing
disabilities
– – – – – 9 – –
Disease-specific
quality of life
– – – – – 6 – –
Life impact core area, 32a: delivery of care—satisfaction / patient preference
Device benefit – – – – 2 8 – –
Device use – – 3 – 1 2 1 1
Satisfaction – – – – 2 5 1 –
Aversiveness – – – – – 1 –
Adverse events core area, 38: adverse events / effects
Adverse effects – – – 1 – 2 – 6
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Table 4 Listing of all unique measurement methods used to assess the most common outcomes in Dodd’s taxonomy physiological
or clinical #6, ear and labyrinth category. Only those domains where there was more than one report of the outcome measurement
method are selected for reporting here. See Additional file 10 for full details




Hearing thresholds, investigator administered
Psychophysical
Pure-tone audiometry 10 –
Pure-tone audiometry (bone conduction only) 2 –
Soundfield audiometry 2 –
Speech in noise, investigator administered
Psychophysical
Bamford-Kowal-Bench Speech in Noise test (BKB-SiN) in four-talker babble, Speech Reception Thresh-
olds (SRT)
3 –
Bamford-Kowal-Bench Speech in Noise test (BKB-SiN) in multi-talker babble, Speech Reception Thresh-
olds (SRT)
2 –
Hearing In Noise Test (HINT) in multi-talker babble, Speech Reception Thresholds (SRT) 2 –
Hearing in Noise Test (HINT) in R-space restaurant noise, Speech Reception Thresholds (SRT) 2 –
Hearing in Noise Test (HINT) noise not specified, Speech Reception Thresholds (SRT) 2 –
Hochmair-Schulz-Moser sentence test in speech-shaped noise, Speech Reception Thresholds (SRT) 3 –
Leuven Intelligibility Sentences Test (LIST) noise not specified, Speech Reception Thresholds (SRT) 2 –
Oldenburg Sentence Test (OlSa) noise not specified, Speech Reception Thresholds (SRT) 5 –
Quick Speech-In-Noise (QuickSIN) test in multi-talker babble, Speech Reception Thresholds (SRT) 2 –
Speech Intelligibility In Noise (SPIN) test in multi-talker babble, percent correct 3 –
Speech-in-noise test in speech (not specified), Speech Reception Thresholds (SRT) 2 –
Speech in noise, PROM
Multi-item questionnaire
APHAB background noise subscale 5 9
Speech in quiet, investigator administered
Psychophysical
Consonant-Nucleus-Consonant (CNC) word list 3 –
Freiburger monosyllabic word discrimination in quiet, Speech Reception Thresholds (SRT) 2 –
Monosyllable test (67S test), Japanese version 2
Speech hearing, PROM
Multi-item questionnaire
Abbreviated Profile of Hearing Aid Benefit (APHAB) ease of communication subscale 5 9
Speech, Spatial and Qualities of Hearing (SSQ) speech subscale 4 9
Tinnitus loudness, investigator administered
Psychophysical
Tinnitus Loudness Matching 1 3
Tinnitus loudness, PROM
Numerical rating scale
Numerical rating scale (not specified) 2 1
Visual analogue scale (not specified) 6 –
Spatial hearing, PROM
Multi-item questionnaire
Speech, Spatial and Qualities of Hearing (SSQ) spatial subscale 3 8
Spatial Hearing Questionnaire (SHQ) 2 –
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number of testing sessions, from a single session to on-
going daily records [50], and when they were conducted
after device fitting or surgery. For reporting, time frames
were grouped into measures taken in a single session
only, at a time point less than 3 months after baseline
(‘acute’), at a time point from 3 months to less than
1 year after intervention (‘early’ acclimatisation) and at
1 year or more after intervention (‘long’). Eighteen of the
72 included studies were designed as a single session (12
rerouting, 5 restoring, 1 both), 26 had at least one acute
follow-up (16 rerouting, 9 restoring, 1 both) mostly at
1 month after baseline, 31 had at least one early follow-
up (11 rerouting, 16 restoring, 4 both) mostly at
6 months after baseline and 26 had at least one long
follow-up (6 rerouting, 16 restoring, 4 both).
We evaluated whether there was any change over time
in the choice of primary and secondary outcome do-
mains and measurement methods by classifying the data
according to the three major Dodd’s taxonomy categories
[90] (#6 Ear and labyrinth, #30 global quality of life and
#32a delivery of care), and according to whether they were
investigator-administered tests or PROMs (Fig. 2).
Single-session studies almost exclusively focused on
hearing-related outcome domains, but ear and labyrinth
accounted for about 50% of the outcomes assessed, even
at the longest time frame. Similarly, single-session stud-
ies almost exclusively used investigator-administered
testing methods, but over time, a more 50/50 balanced
was observed between these and PROMs. This pattern
was true for the primary outcomes. However, secondary
outcomes were almost always used PROMs, irrespective
of the time frame.
Sensitivity analysis
The final, exploratory objective examined whether we
would identify any additional outcomes if we included
Table 4 Listing of all unique measurement methods used to assess the most common outcomes in Dodd’s taxonomy physiological
or clinical #6, ear and labyrinth category. Only those domains where there was more than one report of the outcome measurement
method are selected for reporting here. See Additional file 10 for full details (Continued)




Spatial Hearing Questionnaire (SHQ), various subscales – 8
Localisation, investigator administered
Psychophysical
Horizontal semi-circular array of 7 loudspeakers, angular separation 30  °, localisation accuracy 2 1
Horizontal circular array of 5 loudspeakers, angular separation 45°, localisation accuracy 2 –
Horizontal circular array of 9 out of 33 loudspeakers, angular separation 5.6°, localisation accuracy 1 1
Horizontal circular array of 19 loudspeakers, angular separation 10°, localisation accuracy 2 –
Localisation from one or multiple loudspeakers (not specified) 1 2
Table 5 Listing of all unique measurement methods used to assess the most common outcomes in the Dodd’s taxonomy life
impact #30, global quality of life category [90]. Only those domains where there was more than 1 report of the outcome
measurement instrument are selected for reporting here. See Additional file 10 for full details
Measurement methods (n > 1) split by outcome domains and type of method Primary outcomes Secondary outcomes
Tinnitus-symptom severity, PROM
Multi-item questionnaire Tinnitus Handicap Inventory (THI) 7 1
Tinnitus Questionnaire (TQ) 2 1
Tinnitus Questionnaire (TQ), German version 3 -
Tinnitus Reaction Questionnaire (TRQ) 3 -
Hearing disabilities, PROM
Multi-item questionnaire Speech, Spatial and Qualities of Hearing (SSQ) 8 -
Disease-specific quality of life, PROM
Multi-item questionnaire Bern Benefit in Single Sided Deafness (BBSS) questionnaire 1 1
Glasgow Benefit Inventory (GBI) 3 2
Nijmegen Cochlear Implant Questionnaire (NCIQ) 1 2
Single Sided Deafness (SSD) questionnaire 4 -
Multi-item, multi-domain questionnaire (author's own) - 2
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studies where the audiometric eligibility criteria were
more lenient than our working definition adopted from
the Van de Heyning et al. [1] consensus paper. The out-
come domains reported by the 24 additional studies
were coded in the same way as described previously.
Overall, 205 primary and 80 secondary data items were
categorised. None of these reported outcomes had not
already been captured by the 72 included studies.
Risk of bias
Assessment of the 72 included studies focused on (a)
whether the outcomes were reported prospectively, and
(b) if yes, whether there was consistency between the
prospective registration and the published study. Notes
on conflicts of interest and study design were also taken.
Although there were 11 clinical trial registrations, only
four studies with reported findings had been pre-
registered. One assessed the SoundBite™ [46] and three
assessed cochlear implantation [120, 121, 131]. The
SoundBite™ study had two discrepancies: adverse effects
were not reported in the protocol (NCT01933386) [131]
but were reported in the published record discussion,
and the pure-tone audiometry (PTA) thresholds range
were planned up to 4 kHz in the protocol but reported
up to 2 kHz in the study report. All three cochlear im-
plant studies had discrepancies between the measures
planned in the registered protocol and those actually re-
ported in the study findings. Other discrepancies in-
cluded lack of clarity in the report on whether adverse
events were assessed at 1 month post-implantation, as
per protocol (NCT02259192) [122] and differences be-
tween the planned and reported measurement time
frames (NCT01749592) [121].
Discussion
There is a growing general recognition that insufficient
attention has been paid to the outcomes measured and
reported in clinical trials. The CROSSSD study group
has established the need for a core outcome set for SSD
interventions and we are the first to identify existing
knowledge about outcomes using a systematic review
methodology.
Principal findings
Most studies included in the review evaluated rerouting
interventions rather than restoring interventions. There
was a large variation in the reported outcome domains,
with most studies concentrating on physiological or clin-
ical outcomes, followed by life impact outcomes. Only a
small minority of studies reported on resource use and
adverse events. Investigators did not always report what
their intended outcome domain was, suggesting that
their chosen instruments were not actively matched to
an outcome domain. With regard to instruments chosen
by investigators, a large inconsistency was observed with
investigator-administered tests mostly adopted, focusing
mainly on speech in noise and spatial-related testing. A
diversity within these categories of instruments was also
Table 6 Listing of all unique measurement methods used to assess the most common outcomes in the Dodd’s taxonomy life
impact #32a, Delivery of care (Satisfaction / patient preference) category. Only those domains where there was more than one
report of the outcome measurement instrument are selected for reporting here. See Additional file 10 for full details





Multi-item questionnaire Abbreviated Profile of Hearing Aid Benefit (APHAB) 6 -
Glasgow Hearing Aid Benefit Profile (GHABP) 4 -
Multi-item, multi-domain Questionnaire (author's own) 3 -
Numerical rating scale International Outcome Inventory for Hearing Aids (IOI-HA), single item on
benefit
1 1
Visual Analogue Scale (not specified) 1 -
Device use, investigator administered
Technical and lab
measures
Device log (not specified) 2 -
Device log average usage (hrs / day) 3 -
Device use, PROM
Multi-item questionnaire Glasgow Hearing Aid Benefit Profile (GHABP), hearing aid use subscale 2 -
Satisfaction, PROM
Multi-item questionnaire Glasgow Hearing Aid Benefit Profile (GHABP), various subscales 1 2
Multi-item, multi-domain questionnaire (author's own) 2 -
Aversiveness, PROM
Multi-item questionnaire Abbreviated Profile of Hearing Aid Benefit (APHAB) aversiveness subscale 5 6
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observed with a plethora of signal and noise configura-
tions that do not always fit existing recommendations
that aim to reveal both the benefits and drawbacks of
hearing devices. Similarly, multi-item questionnaires are
frequently utilised but there is no consensus in their se-
lection, nor the intended outcome domains to be mea-
sured. Although the range of functional difficulties
imposed by SSD, as well as the impact on individual’s
social and psychological well-being, are well documented
[17], similar to other interventions in the hearing field,
they are not always assessed in a systematic manner [78,
143, 144]. The time frame when interventions are
assessed also varies, so it is challenging to compare the
short- and long-term treatment-related changes for
rerouting and restoring interventions.
Comparison with other studies
Our review identifies limitations in the range of re-
ported outcomes in clinical trials that are reflected
more broadly across clinical practice in ENT and
audiology. In 2016, Van de Heyning led a several ex-
pert panel discussions to reach a consensus on a clin-
ical protocol for SSD including a minimum set of
outcome measures [1]. This group recommended a
core set of three ear and labyrinth and two life im-
pact measures, tested using investigator-administered
tests and PROMs, respectively. Ear and labyrinth
measures were as follows: (i) hearing thresholds using
pure-tone audiometry, (ii) speech in noise perception
using a standard audiometric and validated sentence
test and a free-field setup in a sound-treated room
and (iii) sound localisation using a free-field system
with at least seven loudspeakers horizontally distrib-
uted with equal angular separation, again in a sound-
treated room. In our review, we observed that these
were some of the most popular domains reported
across the 72 included studies. Common speech in
noise materials included the Hearing in Noise Test
(HINT) sentences, Oldenburg sentence test (OlSa)
and the Speech Intelligibility In Noise (SPIN) test.
Measurements for sound localisation perhaps diverged
the most from this expert panel recommendation,
with numerous studies either using fewer speakers or
testing front and back localisation in a circular array.
Recommended life impact measures were as follows:
(i) quality of life using both disease-specific (speech,
spatial, and qualities of hearing (SSQ)) and generic
health-related (Health Utilities Index (HUI) Mark 3)
questionnaires and (ii) delivery of care using a meas-
ure of device use (data logging or patient report). In
our review, we actually coded the SSQ questionnaire
as an ear and labyrinth assessment (not life impact)
because it was most often reported as separate sub-
scale scores for speech hearing, spatial hearing and
quality of hearing. We also observed that Health Util-
ities Index (HUI-3) [145] was rarely reported across
the 72 included studies (others were EuroQol-5D-3L
[146], WHOQOL-BREF [147] and SF-36 [148]).
Fig. 2 Top panels illustrate reporting of the three major outcome domain taxonomy categories over the successive follow-up time points.
Bottom panels illustrate reporting of the two major measurement methods over time. All data are reported as a percentage, normalised to the
total number of outcome data items assessed at that time point and calculated separately for primary and secondary outcomes
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Van de Heyning et al. [1] also recommended tinnitus
assessment if applicable, namely tinnitus loudness (using
a visual analogue scale (VAS)) and tinnitus symptom se-
verity (using the Tinnitus Functional Index). Our review
confirmed that these domains were often limited to re-
storing interventions (cochlear implant) studies and
therefore were perhaps considered less relevant to
rerouting interventions for SSD by investigators. It is
possible that this recommendation reached consensus
because the panel comprised cochlear implant experts
attending a cochlear implant conference.
In terms of time frame for outcome measurement,
Van de Heyning et al. [1] recommended that outcomes
should be collected at baseline, and at 1, 3, 6 and 12
months after intervention. This would mean that all
studies should span the acute, early and long-term time
points coded in our review. Nevertheless, less than half
of the included studies assessed outcome at these time
points.
Strengths and limitations of the study
Our review was guided by good practice as set out in the
Core Outcome Measures in Effectiveness Trials
(COMET) handbook [77]. In terms of outcome extrac-
tion from the academic literature, Williamson et al. [77]
state ‘it is recommended that all are extracted verbatim
from the source manuscript’. This posed some chal-
lenges when it came to coding the domains because dif-
ferent investigators used different terminology even
when they were probably referring to the same con-
struct. In order to collate the data, our team had to re-
code some of the domain names, conducting this task in
pairs to reduce the impact of individual opinion. For
transparency, we provide the authors’ original descrip-
tion and our recoding in Additional file 7. This allows
external critical review of the CROSSSD core outcome
set, whose development will be informed by this review,
right back to its inception.
There is currently no consensus on how clinical
trial outcomes should be classified [149]. COS re-
searchers often simply agree ‘themes’ in discussion
with advisory groups [150]. However, it is recognised
that this lack of a standardised outcome classification
system results in inconsistencies due to ambiguity and
variation in how outcomes are described across differ-
ent studies. Recently, a new taxonomy for outcome
classification has been developed to promote efficient
searching, reporting and classification of trial out-
comes [90]. Strengths are that it focuses on general
outcomes, is comprehensive, is not disease specific
and is applicable to trials for any disease or health
condition. Although not part of our published proto-
col [87], we felt that it was sufficiently important to
implement this standard taxonomy in this systematic
review. While our findings are presented using this
taxonomy, it was insufficient to delineate the different
outcome domains with the ear and labyrinth category
and so we expanded this category using our own sub-
categories. Again for transparency, we provide full de-
tails of our customised sub-categorisation in
Additional file 10.
Also recommended in the COMET handbook [77] is
to perform the systematic review in stages to check if
outcome saturation is reached. In this sense, our sensi-
tivity analysis can be considered such a check. We had
identified 24 additional studies that just missed the eligi-
bility criteria for inclusion, but none of these studies re-
ported any novel outcome domains that had not already
been captured in the first stage. As Williamson et al.
[77] state ‘If there are no further outcomes of import-
ance then the systematic review may be considered
complete’.
The longer-term intention of this work is to develop
a core outcome set that identifies by consensus a mini-
mum standard for reporting in clinical trials of SSD in
adults. This review makes a specific contribution to
that endeavour by identifying domains that have been
defined in relevant clinical trial designs to date. We rec-
ognise that systematic reviews of outcomes simply ag-
gregate the opinions of previous researchers on what
outcomes they deemed important to measure. The out-
come domains collated in this review will be put for-
ward as potential candidates as outcome domains in a
long list that will be considered by a range of stake-
holders using a Delphi consensus method [77]. For that
long list to be truly comprehensive, it is important to
also give participants the option to nominate any new
domains that they might consider missing. Here, the
patient perspective might be important as they have not
yet hitherto been actively involved in COS decision
making.
Conclusions
This review highlights outcome domains and instruments
reported by studies that have evaluated rerouting and/or
restoring interventions for SSD in adults. The extracted
data provides a meticulous catalogue of investigators’
chosen outcome domains of which the majority were suc-
cessfully categorised using the Dodd et al. [90] taxonomy
outcome classification system. Our findings emphasise the
need to improve trial design and reporting in this area of
health research. We hope that guidelines that have been
developed explicitly with both rerouting and restoring in-
terventions in mind will have broader take up across the
ENT and audiology communities. To improve reporting,
we also draw attention to the specialised CONSORT
guidelines for reporting harms-related issues in a rando-
mised controlled trial [83].
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